The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL
Arnon P. Kater(Amsterdam University Medical Centers), John F. Seymour(The Royal Melbourne Hospital), Rosemary Harrup(University of Tasmania), Yanwen Jiang, Clemens Mellink, Guillaume Cartron(Hôpital Saint Eloi), Thomas J. Kipps(University of California San Diego), Ulrich Jäger(Medical University of Vienna), Marco Montillo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Relja Popovic(Loyola University Medical Center), Carolyn Owen(University of Calgary), Maria Thadani‐Mulero(Roche (United Kingdom)), Brenda Chyla(AbbVie (United States)), Sarit Assouline(Jewish General Hospital), Anton W. Langerak(Erasmus MC), Michelle Boyer(Amgen (United States)), Javier de la Serna(Hospital Universitario 12 De Octubre), Marcus Lefebure(Peter MacCallum Cancer Centre), Tadeusz Robak(Medical University of Lodz), Rosemary Millen(Royal Netherlands Academy of Arts and Sciences), Barbara Eichhorst(University of Cologne), Nicole Lamanna(Memorial Sloan Kettering Cancer Center)
Cited by 55
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k